GSA Capital Partners LLP Purchases New Shares in Protagonist Therapeutics, Inc. $PTGX

GSA Capital Partners LLP purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the third quarter, HoldingsChannel.com reports. The institutional investor purchased 5,884 shares of the company’s stock, valued at approximately $391,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Salomon & Ludwin LLC purchased a new stake in shares of Protagonist Therapeutics in the third quarter valued at $29,000. Bessemer Group Inc. grew its holdings in Protagonist Therapeutics by 171.0% during the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after purchasing an additional 318 shares during the last quarter. CWM LLC grew its holdings in Protagonist Therapeutics by 201.5% during the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock valued at $34,000 after purchasing an additional 407 shares during the last quarter. Abich Financial Wealth Management LLC purchased a new stake in Protagonist Therapeutics in the 3rd quarter worth about $62,000. Finally, Osaic Holdings Inc. lifted its stake in Protagonist Therapeutics by 79.5% in the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after purchasing an additional 525 shares during the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Protagonist Therapeutics news, Director Lewis T. Williams sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $82.42, for a total value of $1,483,560.00. Following the completion of the sale, the director directly owned 7,825 shares in the company, valued at $644,936.50. This trade represents a 69.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 34,438 shares of Protagonist Therapeutics stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $82.48, for a total transaction of $2,840,446.24. Following the completion of the transaction, the chief executive officer directly owned 580,505 shares in the company, valued at $47,880,052.40. This represents a 5.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 203,167 shares of company stock valued at $16,889,199 in the last three months. 4.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Jefferies Financial Group upped their target price on Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Citizens Jmp upped their price objective on Protagonist Therapeutics from $69.00 to $102.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Citigroup increased their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. HC Wainwright boosted their target price on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, Truist Financial raised their price target on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.00.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX opened at $87.10 on Thursday. The company has a market cap of $5.45 billion, a PE ratio of 140.49 and a beta of 2.26. Protagonist Therapeutics, Inc. has a 52-week low of $34.81 and a 52-week high of $96.54. The firm’s 50 day moving average price is $84.07 and its 200-day moving average price is $76.51.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Friday, February 27th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. On average, analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.